	US 12,000,830 B2
	Serological assay for the detection of zika virus-specific antibodies utilizing overlapping peptides comprising an NS2B epitope
Walter Ian Lipkin, New York, NY (US); Nischay Mishra, New York, NY (US); Thomas Briese, White Plains, NY (US); and Adrian Caciula, New York, NY (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US)
Appl. No. 16/466,161
Filed by THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
PCT Filed Dec. 1, 2017, PCT No. PCT/US2017/064167 § 371(c)(1), (2) Date Jun. 3, 2019, PCT Pub. No. WO2018/102659, PCT Pub. Date Jun. 7, 2018.
Claims priority of provisional application 62/428,845, filed on Dec. 1, 2016.
Prior Publication US 2019/0359694 A1, Nov. 28, 2019
Int. Cl. G01N 33/569 (2006.01); A61K 35/76 (2015.01); C07K 7/00 (2006.01); C07K 16/06 (2006.01); C07K 16/10 (2006.01)

CPC G01N 33/56983 (2013.01) [A61K 35/76 (2013.01); C07K 7/00 (2013.01); C07K 16/06 (2013.01); C07K 16/1081 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); G01N 2333/185 (2013.01)]

20 Claims

1. A method for the serological detection of an antibody to Zika virus in a sample, comprising:

a. contacting the sample with a collection of isolated non-redundant peptides specific for antibodies to Zika virus, wherein the peptides are 5 amino acids to 20 amino acids in length of the sequences set forth in SEQ ID NO: 1 or SEQ ID NOS:14-22, under conditions sufficient to allow the binding of the antibody(ies) to the peptide(s);

b. washing antibodies that have not bound to the isolated non-redundant peptides;

c. labeling bound antibodies with a detectable label; and

d. detecting formation of an antibody-peptide complex comprising said one or more peptides in the collection,

wherein formation of the complex is indicative of an antibody to an epitope of a Zika antigen being present in the sample.